• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Faze Medicines Inc.

Headquarters: Cambridge, MA, United States
Website: N/A
Year Founded: 2020
Status: Out of Business

BioCentury | Sep 11, 2023
Management Tracks

Sanofi alum Sibold named CEO at Madrigal

Plus: Fenimore to succeed Landry as Regeneron CFO and updates from SpringWorks, SalioGen, Oxular, Solu, Flagship, Oculis
Read More
BioCentury | Nov 11, 2022
Regulation

Nov. 10 Quick Takes: BrainStorm falls on refusal-to-file letter from FDA

Plus: AZ dropping U.S. plans for Vaxzevria and updates from Neuraxpharm, Minoryx and more
Read More
BioCentury | Aug 31, 2022
Management Tracks

Overall B minus — rank and file give management a lukewarm grade

New era, old problems, puts pressure on the C-suite to adapt
Read More
BioCentury | Aug 30, 2022
Management Tracks

Rising leaders want management to lift the curtain, then open the door

Making the right connections, getting the right experience are the biggest hurdles to joining the C-suite
Read More
BioCentury | Aug 6, 2021
Management Tracks

New CMO, CSO at Black Diamond

Plus updates from Adaptive, Homology and more
Read More
BioCentury | Jan 27, 2021
Management Tracks

Novartis’ chief digital officer stepping down; plus moves at Taysha, Roivant, Faze and more

Bertrand Bodson, chief digital officer at Novartis AG (NYSE:NVS; SIX:NOVN), will step down from the pharma’s executive committee on Feb. 1. Bodson took on the newly created role at Novartis in
Read More
BioCentury | Dec 11, 2020
Emerging Company Profile

Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology

Emerging Company Profile: dissecting normal and pathogenic biomolecular condensate biology to enable drug development
Read More
Items per page:
1 - 7 of 7